ZA201203614B - Pyrazine derivatives and their use in the treatment of neurological disorders - Google Patents

Pyrazine derivatives and their use in the treatment of neurological disorders

Info

Publication number
ZA201203614B
ZA201203614B ZA2012/03614A ZA201203614A ZA201203614B ZA 201203614 B ZA201203614 B ZA 201203614B ZA 2012/03614 A ZA2012/03614 A ZA 2012/03614A ZA 201203614 A ZA201203614 A ZA 201203614A ZA 201203614 B ZA201203614 B ZA 201203614B
Authority
ZA
South Africa
Prior art keywords
treatment
neurological disorders
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
ZA2012/03614A
Other languages
English (en)
Inventor
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201203614(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201203614B publication Critical patent/ZA201203614B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/03614A 2009-12-31 2012-05-17 Pyrazine derivatives and their use in the treatment of neurological disorders ZA201203614B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31
PCT/EP2010/070502 WO2011080176A1 (en) 2009-12-31 2010-12-22 Pyrazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
ZA201203614B true ZA201203614B (en) 2013-01-30

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/03614A ZA201203614B (en) 2009-12-31 2012-05-17 Pyrazine derivatives and their use in the treatment of neurological disorders

Country Status (27)

Country Link
US (2) US20120277244A1 (enExample)
EP (1) EP2519515B1 (enExample)
JP (1) JP5600754B2 (enExample)
KR (1) KR101419157B1 (enExample)
CN (1) CN102712621B (enExample)
AU (1) AU2010338365B2 (enExample)
BR (1) BR112012015916A2 (enExample)
CA (1) CA2785341A1 (enExample)
CL (1) CL2012001762A1 (enExample)
CR (1) CR20120332A (enExample)
CU (1) CU20120099A7 (enExample)
EA (1) EA201200952A1 (enExample)
EC (1) ECSP12012065A (enExample)
ES (1) ES2445536T3 (enExample)
GT (1) GT201200219A (enExample)
HN (1) HN2012001413A (enExample)
IL (1) IL220268A0 (enExample)
MX (1) MX2012007754A (enExample)
NZ (1) NZ600136A (enExample)
PE (1) PE20121640A1 (enExample)
PH (1) PH12012501007A1 (enExample)
PL (1) PL2519515T3 (enExample)
PT (1) PT2519515E (enExample)
SG (1) SG181431A1 (enExample)
TN (1) TN2012000249A1 (enExample)
WO (1) WO2011080176A1 (enExample)
ZA (1) ZA201203614B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
RU2476430C2 (ru) 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина, замещенные циклической группой
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011071135A1 (ja) 2009-12-11 2011-06-16 塩野義製薬株式会社 オキサジン誘導体
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
PH12012502377A1 (en) 2010-06-09 2014-10-14 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
EP2655376B1 (en) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
US20140128385A1 (en) * 2011-01-13 2014-05-08 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
CN103403001B (zh) * 2011-01-13 2016-08-17 诺瓦提斯公司 杂环衍生物及其在神经性疾病治疗中的应用
MY161407A (en) 2011-03-01 2017-04-14 Janssen Pharmaceutica Nv 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
SG193342A1 (en) 2011-03-09 2013-10-30 Janssen Pharmaceutica Nv 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2013150349A (ru) 2011-04-13 2015-05-20 Мерк Шарп И Доум Корп. 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
AU2014280124B2 (en) 2013-06-12 2018-11-01 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
JP6387402B2 (ja) 2013-06-12 2018-09-05 ヤンセン ファーマシューティカ エヌ.ベー. β−セクレターゼ(BACE)の阻害剤としての4−アミノ−6−フェニル−5,6−ジヒドロイミダゾ[1,5−A]ピラジン−3(2H)−オン誘導体
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
CN107108582B (zh) 2014-12-18 2019-10-18 詹森药业有限公司 β-分泌酶的2,3,4,5-四氢吡啶-6-胺化合物抑制剂
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (enExample) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
BRPI0418212A (pt) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
CN103936690B (zh) * 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
KR101331768B1 (ko) * 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Atp 결합 카세트 수송체의 헤테로사이클릭 조정제
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
CA2785341A1 (en) 2011-07-07
PL2519515T3 (pl) 2014-04-30
HN2012001413A (es) 2015-03-23
EP2519515A1 (en) 2012-11-07
WO2011080176A1 (en) 2011-07-07
MX2012007754A (es) 2012-08-01
PH12012501007A1 (en) 2013-01-14
EA201200952A1 (ru) 2013-02-28
AU2010338365B2 (en) 2014-01-30
KR101419157B1 (ko) 2014-07-11
US20120277244A1 (en) 2012-11-01
NZ600136A (en) 2013-09-27
JP2013516395A (ja) 2013-05-13
US20150322038A1 (en) 2015-11-12
PE20121640A1 (es) 2012-12-17
KR20120102795A (ko) 2012-09-18
CU20120099A7 (es) 2012-07-31
JP5600754B2 (ja) 2014-10-01
CN102712621A (zh) 2012-10-03
TN2012000249A1 (en) 2013-12-12
CR20120332A (es) 2012-07-12
GT201200219A (es) 2013-10-10
EP2519515B1 (en) 2013-11-06
ECSP12012065A (es) 2012-08-31
ES2445536T3 (es) 2014-03-03
CN102712621B (zh) 2015-03-11
IL220268A0 (en) 2012-07-31
CL2012001762A1 (es) 2012-12-21
SG181431A1 (en) 2012-07-30
HK1172023A1 (en) 2013-04-12
AU2010338365A1 (en) 2012-06-07
BR112012015916A2 (pt) 2017-04-25
PT2519515E (pt) 2014-02-17

Similar Documents

Publication Publication Date Title
IL220268A0 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
IL218034A0 (en) Oxazine derivatives and their use in the treatment of neurological disorders
AP3807A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
ZA201109384B (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
ZA201100482B (en) Pyrazolopyrimidines and their use for the treatment of cns disorders
IL205108A0 (en) Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP2278972A4 (en) TREATMENT FOR NEUROLOGICAL AND MENTAL DISORDERS
GB0904044D0 (en) The treatment of inflammatory disorders and pain
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
HUE047515T2 (hu) N-Szubsztituált benzolpropánamidok fájdalom és gyulladás kezelésében történõ alkalmazásra
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB0814043D0 (en) The treatment of skin disorders
GB0803397D0 (en) The treatment of inflammatory disorders and pain
GB0817330D0 (en) The treatment of inflammatory disorders and pain
GB0703494D0 (en) The treatment of inflammatory disorders and pain
GB0722524D0 (en) The treatment of inflammatory disorders and pain
GB0718279D0 (en) The treatment of inflammatory disorders and pain
GB0711769D0 (en) The treatment of inflammatory disorders and pain
AU2010901520A0 (en) Substituted thienobenzodiazepines and their use in the treatment of CNS disorders